November 25, 2015: The FDA Peripheral and Central Nervous System Drugs Advisory Committee met yesterday to discuss BioMarin’s Kyndrisa (drisapersen) for Duchenne muscular dystrophy (DMD) and it was not pretty.
November 25, 2015: One of the side aspects of the pending Pfizer-Allergan deal, is that Pfizer will end up owning a 10 percent share in Israel-based Teva. In July, Teva acquired Allergan’s generic drug business for $40.5B.
November 25, 2015: Inside sources have indicated that Shire is preparing another bid for Baxalta. In July, Shire made a bid for Baxalta, and when that wasn’t accepted, Shire went public with the offer in early August.
November 25, 2015: Turing Pharma announced yesterday a 50 percent cut in its prices for toxoplasmosis drug Daraprim. Turing and its CEO Martin Shkreli became the focus of a national discussion of drug pricing in August after it acquired Daraprim from IMPAX Labs for $55M.